ES2524021T3 - Formas cristalinas del ácido (3S)-3-[N-(N'-(2-terc-butilfenil)oxamil)alaninil]amino-5-(2',3',5',6'-tetrafluorofenoxi)-4-oxopentanoico - Google Patents

Formas cristalinas del ácido (3S)-3-[N-(N'-(2-terc-butilfenil)oxamil)alaninil]amino-5-(2',3',5',6'-tetrafluorofenoxi)-4-oxopentanoico Download PDF

Info

Publication number
ES2524021T3
ES2524021T3 ES07859033.8T ES07859033T ES2524021T3 ES 2524021 T3 ES2524021 T3 ES 2524021T3 ES 07859033 T ES07859033 T ES 07859033T ES 2524021 T3 ES2524021 T3 ES 2524021T3
Authority
ES
Spain
Prior art keywords
medium
weak
tetrafluorophenoxy
alaninyl
oxopentanoic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07859033.8T
Other languages
English (en)
Inventor
Stuart Dimock
Eric Hagen
Jason Hanko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Histogen Inc
Original Assignee
Conatus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conatus Pharmaceuticals Inc filed Critical Conatus Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2524021T3 publication Critical patent/ES2524021T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/74—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/52—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Una forma cristalina del ácido (3S)-3-[N-(N'-(2-terc-butilfenil)oxamil)alaninil]amino-5-(2',3',5',6'- tetrafluorofenoxi)-4-oxopentanoico.

Description

imagen1
imagen2
E07859033
14-11-2014
Cuando se analiza por espectroscopia de Raman de transformada de Fourier la Forma I muestra picos característicos a longitud de onda de 3356 (débil), 3262 (medio), 3086 (medio), 2959 (fuerte), 2939 (fuerte), 1742 (medio), 1695 (medio fuerte), 1647 (débil), 1601 (débil), 1541 (medio), 1451 (débil), 1399 (débil), 1336 (medio), 1271 (medio fuerte), 1135 (débil), 1054 (medio), 1031 (débil), 977 (medio), 930 (débil), 888 (medio), 859 (débil), 817
5 (débil), 716 (medio), 688 (medio), 568 (medio), 479 (medio), 439 (débil), 398 (medio), 340 (débil), 223 (débil) cm-1 (± 2 cm-1 excepto para los picos a 2959, 1541, 1451, 1271, 1135, 1054, 1031, 977, 930, 888, 859, 716, 688, 568, 479, 439, 398 y 223 donde los límites de error son (± 5 cm-1). Las asignaciones de intensidad (débil, medio, medio fuerte, fuerte) son en relación con el pico principal del espectro. El espectro se reproduce en la Figura 6.
La Forma II muestra un pico endotérmico agudo a 157° C (± 2° C) cuando se analiza por DSC (véase la Figura 7).
10 La Forma II muestra picos únicos de difracción a 14,5, 17,3, 22,5, 25,0 y 26,8 grados dos theta (± 0,1 grados) cuando se analiza por PXRD (véase la Figura 8). Un listado de picos se proporciona a continuación en la Tabla 3.
Tabla 3 - Datos de PXRD de la Forma II
Ángulo 2-Theta (grados)
Intensidad relativa (%) Ángulo 2-Theta (grados) Intensidad relativa (%) Ángulo 2-Theta (grados) Intensidad relativa (%)
4,0
100,0 21,7 27,4 30,9 10,7
7,4
27,2 21,8 28,5 31,7 15,0
12,0
16,6 22,5 15,9 32,5 12,6
14,5
12,9 23,3 31,2 33,0 12,2
14,8
13,7 23,8 36,2 33,3 14,1
15,6
31,2 24,2 32,1 35,2 12,2
16,1
35,0 25,0 24,6 36,0 20,1
17,3
21,9 25,5 16,0 36,6 12,6
17,9
14,1 25,7 14,3 37,1 15,7
18,1
11,3 26,3 13,0 37,3 14,1
18,8
44,1 26,8 15,6 37,7 15,9
19,4
37,4 28,9 17,3 38,1 13,8
20,2
33,8 29,1 19,3 39,0 17,2
20,4
36,5 30,0 22,5
21,1
14,2 30,5 13,2
La Forma II muestra desplazamientos químicos únicos a 136,2, 131,6, 126,1, 30,4 y 17,7 ppm cuando se analiza por
15 13C RMN de fase sólida utilizando una muestra externa de adamantina de fase sólida a 29,5 ppm como referencia. El espectro de 13C RMN observado se reproduce en la Figura 9 (los picos marcados con un asterisco son bandas laterales de giro) y el listado de picos completo se proporciona en la Tabla 4 a continuación. Los valores de intensidad son una medida de la altura del pico y éstos pueden variar según los parámetros experimentales establecidos durante la adquisición de datos y la historia térmica de la muestra - no están por lo tanto destinados a
20 tener un significado cuantitativo.
Tabla 4 - Datos de 13C RMN para la Forma II
Desplazamiento químico de 13C (ppm)
Intensidad Desplazamiento químico de 13C (ppm) Intensidad Desplazamiento químico de 13C (ppm) Intensidad
204,8
4,1 141,8 1,2 102,1 2,5
204,0
4,0 139,9 1,5 101,1 2,4
175,5
5,8 138,5 3,4 76,6 2,9
175,3
5,9 136,2 3,0 57,5 4,8
173,0
4,4 133,9 2,5 56,9 4,4
172,7
4,4 132,9 3,3 48,7 5,3
160,4
9,4 131,6 3,8 35,1 7,4
159,1
2,7 130,4 1,0 32,0 12,0
148,0
5,0 128,5 3,1 31,0 10,3
4
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18

Claims (1)

  1. imagen1
ES07859033.8T 2006-12-06 2007-12-03 Formas cristalinas del ácido (3S)-3-[N-(N'-(2-terc-butilfenil)oxamil)alaninil]amino-5-(2',3',5',6'-tetrafluorofenoxi)-4-oxopentanoico Active ES2524021T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86874806P 2006-12-06 2006-12-06
US868748P 2006-12-06
PCT/IB2007/003900 WO2008068615A1 (en) 2006-12-06 2007-12-03 Crystalline forms of ( 3 s ) -3- [n- (n' - (2-tert-butylphenyl) oxamyl) alaninyl] amino-5- (2 ', 3 ', 5 ', 6 ' -tetrafluoro phenoxy) -4-0x0penta noic acid

Publications (1)

Publication Number Publication Date
ES2524021T3 true ES2524021T3 (es) 2014-12-03

Family

ID=39205161

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07859033.8T Active ES2524021T3 (es) 2006-12-06 2007-12-03 Formas cristalinas del ácido (3S)-3-[N-(N'-(2-terc-butilfenil)oxamil)alaninil]amino-5-(2',3',5',6'-tetrafluorofenoxi)-4-oxopentanoico

Country Status (22)

Country Link
US (1) US7692038B2 (es)
EP (1) EP2091910B1 (es)
JP (1) JP5495787B2 (es)
KR (1) KR101125932B1 (es)
CN (3) CN101573328B (es)
AR (1) AR064809A1 (es)
AU (1) AU2007330478B2 (es)
CA (1) CA2669849C (es)
CL (1) CL2007003491A1 (es)
DK (1) DK2091910T3 (es)
ES (1) ES2524021T3 (es)
HN (1) HN2007000536A (es)
IL (1) IL198732A (es)
MX (1) MX2009006055A (es)
NO (1) NO338908B1 (es)
PA (1) PA8759501A1 (es)
PE (1) PE20081251A1 (es)
PL (1) PL2091910T3 (es)
PT (1) PT2091910E (es)
TW (1) TWI345466B (es)
UY (1) UY30758A1 (es)
WO (1) WO2008068615A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2534153B2 (en) * 2010-02-12 2024-05-22 Pfizer Inc. Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
CN103113405B (zh) * 2012-10-17 2016-03-02 上海日馨生物科技有限公司 苯磷硫胺多晶型体、制备方法及其应用
KR20240010105A (ko) * 2014-03-14 2024-01-23 아지오스 파마슈티컬스 아이엔씨. 치료적으로 활성인 화합물의 약제학적 조성물
ES2751652T3 (es) 2014-05-12 2020-04-01 Conatus Pharmaceuticals Inc Tratamiento con inhibidor de caspasa emricasan de las complicaciones por las enfermedades hepáticas crónicas
SI3977993T1 (sl) * 2014-09-08 2024-05-31 Pfizer Inc. Kristalne trdne oblike 6-karboksi-2-(3,5-diklorofenil)-benzoksazola za uporabo kot zdravilo
AU2016211246B2 (en) * 2015-01-30 2020-08-27 Biomed Valley Discoveries, Inc. Crystalline forms of C21H22CI2N4O2
EP3265440A1 (en) 2015-03-06 2018-01-10 Concert Pharmaceuticals Inc. Deuterated emricasan
CN105017061B (zh) * 2015-07-07 2017-03-29 苏州富士莱医药股份有限公司 一种恩利卡生的合成方法
WO2017079566A1 (en) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Caspase inhibitors for use in the treatment of liver cancer
JP2019500397A (ja) 2015-12-31 2019-01-10 クオナトウス ファーマシューティカルズ，インコーポレイテッド カスパーゼ阻害剤を肝疾患の治療に使用する方法
RU2019113150A (ru) 2016-10-05 2020-11-06 Новартис Аг Комбинация композиций, содержащих агонисты fxr, предназначенная для лечения или предупреждения фиброзирующего, цирротического заболевания или нарушения
WO2018133870A1 (zh) * 2017-01-23 2018-07-26 正大天晴药业集团股份有限公司 作为Caspase抑制剂的联环化合物
JP2019514862A (ja) * 2017-03-23 2019-06-06 ノバルティス アーゲー （ｓ）−２−（ジフェニルアセチル）−１，２，３，４−テトラヒドロ−６−メトキシ−５−（フェニルメトキシ）−３−イソキノリンカルボン酸ナトリウムの無水結晶形
AU2018246255B2 (en) * 2017-03-30 2021-07-08 Merck Patent Gmbh Crystalline form of (s)-(2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl)-(6-methoxy-pyridazin-3-yl)-methanol
AR114251A1 (es) * 2018-02-13 2020-08-12 Syngenta Participations Ag Formas cristalinas de n-[2-(2,4-diclorofenil)ciclobutil]-2-(trifluorometl)piridin-3-carboxamida
US11447497B2 (en) 2018-06-29 2022-09-20 Histogen, Inc. (S)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
PL3935042T3 (pl) 2019-03-07 2024-11-04 Nobo Medicine Inc. Inhibitory kaspazy i sposoby ich zastosowania
EP4027999B1 (en) * 2019-09-10 2026-03-04 Mirati Therapeutics, Inc. Crystalline form of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof
CN111351780A (zh) * 2019-12-29 2020-06-30 中船重工（邯郸）派瑞特种气体有限公司 一种三氟甲基磺酰氟电解槽中电解液成分的分析方法
EP4138843A4 (en) 2020-04-23 2024-07-10 Southern Research Institute COMPOSITION FOR THE TREATMENT OF BLOOD CANCER USING 4'-THIO-5-AZA-2'-DEOXYCYTIDINE AND USES THEREOF
WO2022020747A1 (en) * 2020-07-23 2022-01-27 Southern Research Institute Polymorophs of 5-aza-4'-thio-2-deoxycytidine
WO2022123062A1 (en) 2020-12-11 2022-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Blocking caspase and/or fasl for preventing fatal outcome in covid-19 patients
KR102670554B1 (ko) 2022-01-04 2024-05-30 주식회사 이노보테라퓨틱스 캐스파제 저해제로서의 신규한 이소인돌리논 유도체 화합물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10199058I2 (de) * 1991-07-30 2006-04-27 Alcm Co Kristalle von N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanin und Verfahren zu ihrer Herstellung
DE59307210D1 (de) * 1993-05-12 1997-10-02 Heumann Pharma Gmbh & Co Stabile und kristalline Form von Bezafibrat
US7053056B2 (en) * 1998-07-02 2006-05-30 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6544951B2 (en) * 1998-07-02 2003-04-08 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6197750B1 (en) * 1998-07-02 2001-03-06 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
GB9923933D0 (en) * 1999-10-08 1999-12-08 Smithkline Beecham Lab Novel pharmaceutical
CN1312121C (zh) * 2001-12-11 2007-04-25 杏林制药株式会社 取代苯基丙酸衍生物的新的稳定结晶及其制造方法
CA2614622A1 (en) * 2005-07-11 2007-01-18 Pfizer Limited New combination of anti-madcam antibody and antifibrotic caspase inhibitor to treat liver fibrosis

Also Published As

Publication number Publication date
TW200833319A (en) 2008-08-16
JP2010511689A (ja) 2010-04-15
CN101573328A (zh) 2009-11-04
PA8759501A1 (es) 2009-04-23
CN101573328B (zh) 2014-04-02
CA2669849A1 (en) 2008-06-12
CN103923169A (zh) 2014-07-16
CA2669849C (en) 2012-01-31
NO20091892L (no) 2009-06-17
AU2007330478B2 (en) 2011-09-08
PL2091910T3 (pl) 2015-02-27
KR20090080113A (ko) 2009-07-23
CN103951583B (zh) 2016-01-06
AR064809A1 (es) 2009-04-29
WO2008068615A8 (en) 2009-05-28
KR101125932B1 (ko) 2012-03-22
PE20081251A1 (es) 2008-09-17
UY30758A1 (es) 2008-07-31
HN2007000536A (es) 2011-01-17
NO338908B1 (no) 2016-10-31
CL2007003491A1 (es) 2008-06-20
JP5495787B2 (ja) 2014-05-21
CN103923169B (zh) 2017-05-24
HK1200440A1 (zh) 2015-08-07
DK2091910T3 (en) 2014-12-01
HK1138567A1 (en) 2010-08-27
CN103951583A (zh) 2014-07-30
EP2091910B1 (en) 2014-08-20
PT2091910E (pt) 2014-11-18
US20080249031A1 (en) 2008-10-09
MX2009006055A (es) 2009-06-16
IL198732A0 (en) 2010-02-17
HK1199885A1 (zh) 2015-07-24
TWI345466B (en) 2011-07-21
WO2008068615A1 (en) 2008-06-12
IL198732A (en) 2014-02-27
EP2091910A1 (en) 2009-08-26
US7692038B2 (en) 2010-04-06
AU2007330478A1 (en) 2008-06-12

Similar Documents

Publication Publication Date Title
ES2524021T3 (es) Formas cristalinas del ácido (3S)-3-[N-(N'-(2-terc-butilfenil)oxamil)alaninil]amino-5-(2',3',5',6'-tetrafluorofenoxi)-4-oxopentanoico
Hadjoudis et al. Photochromism and thermochromism of solid trans-N, N′-bis-(salicylidene)-1, 2-cyclohexanediamines and trans-N, N′-bis-(2-hydroxy-naphylidene)-1, 2-cyclohexanediamine
He et al. A divergent route to core-and peripherally functionalized diazacoronenes that act as colorimetric and fluorescence proton sensors
KR102315630B1 (ko) 중합성 화합물, 중합성 조성물, 고분자, 및 광학 이방체
Vijayan et al. Growth and characterization of benzimidazole single crystals: a nonlinear optical material
KR102273081B1 (ko) 중합성 화합물, 중합성 조성물, 고분자, 및 광학 이방체
KR102193544B1 (ko) 중합성 화합물, 중합성 조성물, 고분자, 및 광학 이방체
Hua et al. The substituent effect on the MLCT excited state dynamics of Cu (I) complexes studied by femtosecond time-resolved absorption and observation of coherent nuclear wavepacket motion
Luňák Jr et al. Absorption and fluorescence of soluble polar diketo-pyrrolo-pyrroles
KR102085198B1 (ko) 중합성 화합물의 제조 중간체 및 그 제조 방법
Hinterberger et al. Microwave-assisted one-step synthesis of white light-emitting carbon dot suspensions
ES2524380T3 (es) Sales de raltegravir y formas cristalinas de las mismas
AR050374A1 (es) Forma polimorfica de rafampicina
Ramalingam et al. FTIR and FTRaman spectroscopic investigation of 2-bromo-4-methylaniline using ab initio HF and DFT calculations
JPWO2015122384A1 (ja) 重合性化合物、重合性組成物、高分子、及び光学異方体
Sundar et al. Synthesis of enantiomerically pure helicene like bis-oxazines from atropisomeric 7, 7′-dihydroxy BINOL: preliminary measurements of the circularly polarized luminescence
AR065896A1 (es) Formas cristalinas de [3-(4-{2 butil-1-[4-(4-cloro-fenoxi)-fenil]-1h-imidazol-4-il}-fenoxi)-propil]dietil-amina
Benedetti et al. Synthesis and photophysical studies of through-space conjugated [2.2] paracyclophane-based naphthalene fluorophores
Sánchez et al. Optical and morphological changes in the solid state of chiral imines bearing halogen substituents (F, Cl, and Br)
Petrykowski et al. Double helicene possessing B–N dative bonds built on 1, 4-dihydropyrrolo [3, 2-b] pyrrole core
Dukši et al. Novel bis-phenanthridine derivatives with easily tunable linkers, study of their interactions with DNA and screening of antiproliferative activity
Mitterdorfer et al. Local structural order in carbonic acid polymorphs: Raman and FT‐IR spectroscopy
Lao et al. Electronic and vibrational spectra of a series of substituted carbazole derivatives
Fukumoto et al. Syntheses and photochromic properties of diaryl acenaphthylene derivatives
Naito et al. Quadruply N-methylated octaphyrin: a helical macrocycle exhibiting chiroptical properties and dynamic conformation changes correlated with helical and inner N-methyl orientations